Drug sensitivity analysis of clopidogrel combined with aspirin in the treatment of CHD complicated with eGFR reduction

ObjectiveTo explore the drug sensitivity of clopidogrel combined with aspirin in the treatment of coronary heart disease(CHD) with glomerular filtration rate(eGFR) reduction, and analyze its influence on the inhibition rate of ADP receptor.

MethodsThe clinical data of 233 CHD patients diagnosed by coronary angiography were retrospectively analyzed.According to the presence or absence of eGFR reduction, 233 patients were divided into the CHD without eGFR reduction group(135 cases) and CHD with eGFR reduction group(98 cases).All patients were treated with 300 mg clopidogrel combined with 0.3 g aspirin or 75 mg/d clopidogrel combined with 0.1 g/d aspirin for more than 1 week after PCI.The inhibition rate of ADP receptor and sensitivity to clopidogrel and aspirin were compared between two groups.

ResultsThe inhibition rate of ADP receptor in CHD with eGFR reduction group(55.9±26.8)% was significantly lower than that in CHD without eGFR reduction group(65.7±23.3)%(t=8.932, P < 0.05).The sensitivity rates of clopidogrel and aspirin in CHD with eGFR reduction group were 80.61% and 87.76%, respectively, while which in CHD without eGFR reduction group were 87.41% and 87.41%, respectively.The differences of the sensitivity rates of clopidogrel and aspirin were not statistically significant between two groups(P>0.05).

ConclusionsCompared with the CHD patients without eGFR reduction, the inhibition rate of ADP receptor in CHD patients with eGFR reduction decreases.